Brian K. Albrecht

BRD4 is an atypical kinase that phosphorylates Serine2 of the RNA Polymerase II carboxy-terminal domain

Ballachanda N. Devaiah, Brian A. Lewis, Natasha Cherman et al. · Proceedings of the National Academy of Sciences · 2012 · 378 citations · Full text

Life Sciences, Molecular Biology, Oncology +16

An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells

Maia Vinogradova, Victor Gehling, Amy Gustafson et al. · Nature Chemical Biology · 2016 · 357 citations · Full text

Medicine, Oncology, Pharmacology +14

Identification of (<i>R</i>)-<i>N</i>-((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1<i>H</i>-indole-3-carboxamide (CPI-1205), a Potent and Selective Inhibitor of Histone Methyltransferase EZH2, Suitable for Phase I Clinical Trials for B-Cell Lymphomas

Rishi G. Vaswani, Victor Gehling, Les A. Dakin et al. · Journal of Medicinal Chemistry · 2016 · 220 citations · Full text

Medicine, Oncology, Pharmacology +16

Identification of a Benzoisoxazoloazepine Inhibitor (CPI-0610) of the Bromodomain and Extra-Terminal (BET) Family as a Candidate for Human Clinical Trials

Brian K. Albrecht, Victor Gehling, Michael C. Hewitt et al. · Journal of Medicinal Chemistry · 2016 · 215 citations · Full text

Medicine, Oncology, Pharmacology +15

Identification of EZH2 and EZH1 Small Molecule Inhibitors with Selective Impact on Diffuse Large B Cell Lymphoma Cell Growth

Shivani Garapaty-Rao, Christopher G. Nasveschuk, Alexandre Gagnon et al. · Chemistry & Biology · 2013 · 154 citations

Medicine, Oncology, Pharmacology +8